Info: Read More
  • 中药标准品生产商,产品定制服务
  • 黄连碱

    Coptisine

    黄连碱
    产品编号 CFN99563
    CAS编号 3486-66-6
    分子式 = 分子量 C19H14NO4 = 320.32
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Alkaloids
    植物来源 The herbs of Chelidonium majus L.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    黄连碱 CFN99563 3486-66-6 10mg QQ客服:2056216494
    黄连碱 CFN99563 3486-66-6 20mg QQ客服:2056216494
    黄连碱 CFN99563 3486-66-6 50mg QQ客服:2056216494
    黄连碱 CFN99563 3486-66-6 100mg QQ客服:2056216494
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • Heinrich-Heine-University Düsseldorf (Germany)
  • Instytut Nawozów Sztucznych w Pu?awach (Poland)
  • University of Oslo (Norway)
  • Melbourne University (Australia)
  • Rio de Janeiro State University (Brazil)
  • University of Melbourne (Australia)
  • University of Maryland (USA)
  • Shanghai University of TCM (China)
  • Funda??o Universitária de Desenvolvimento (Brazil)
  • University of Hull (United Kingdom)
  • National Cancer Center Research Institute (Japan)
  • Regional Crop Research Institute (Korea)
  • Medical University of South Carolina (USA)
  • Instituto de Investigaciones Agropecuarias (Chile)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Front Pharmacol.2022, 13:972825.
  • Vietnam J. Chemistry2022, 60(2):211-222
  • BMC Complement Altern Med.2014, 14:352
  • Food Research International2020, 108987
  • Biomedicines.2020, 8(11):486.
  • Food Analytical Methods2020, 13,1603-1612(2020)
  • Food Chem.2021, 360:130063.
  • J Chromatogr Sci.2020, 58(6):485-493.
  • J Sci Food Agric.2018, 98(3):1153-1161
  • J Health Sci Med Res.2023, 31584.
  • J Biochem Mol Toxicol.2021, 35(5):e22731.
  • Agronomy2022, 12(10), 2426.
  • LWT2021, 138:110630.
  • Neurochem Int.2018, 121:114-124
  • Molecules.2021, 26(8):2161.
  • Tropical Journal of Pharmaceutical Research 2021, 20(6):1165-1170.
  • Life Sci.2021, 270:119074.
  • Horticulturae2023, 9(2), 213.
  • Phytomedicine.2022, 102:154183.
  • Korean J Dent Mater.2018, 45(2):139-146
  • Appl Biochem Biotechnol.2022, s12010-022-04166-2.
  • Molecules.2023, 28(9):3685.
  • J Ethnopharmacol.2020, 249:112396
  • ...
  • 生物活性
    Description: Coptisine is an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM, it can consequently prevent neuron loss, reduce amyloid plaque formation, and ameliorate impaired cognition, it could as a potential new class of drugs for AD treatment. Coptisine has cardioprotection, anti- hypercholesterolemia, anti-fungal, anti-osteosarcoma, anti-hepatoma and anti-leukaemia activities, it also has antispasmodic and relaxant activity on a guinea-pig ileum.
    Targets: LDL | P450 (e.g. CYP17) | CDK | Bcl-2/Bax | Caspase | IL Receptor | ROCK | TNF-α | Rho | IDO
    In vitro:
    J Appl Microbiol. 2009 Oct;107(4):1072-80.
    Investigation of the anti-fungal activity of coptisine on Candida albicans growth by microcalorimetry combined with principal component analysis.[Pubmed: 19426275]
    This study investigated the anti-fungal activity of coptisine on Candida albicans growth.
    METHODS AND RESULTS:
    The metabolic power-time curves of Candida albicans growth at 37 degrees C affected by coptisine were measured by microcalorimetry using an LKB-2277 Bioactivity Monitor with stop-flow mode. Then, the diameter of inhibitory zones in the agar layer was observed using agar cup method, and the minimal inhibitory concentration (MIC) of coptisine on Candida albicans growth was determined by serial dilution method. From the principal component analysis on nine quantitative parameters obtained from the power-time curves, we could easily evaluate the anti-fungal activity of coptisine by analysing the change of values of the main two parameters, growth rate constant k and maximum power output in the log phase P(m, log). The results showed that coptisine had strong anti-fungal activity: at a low concentration (45 microg ml(-1)) began to inhibit the growth of Candida albicans and at a high concentration (500 microg ml(-1)) completely inhibited Candida albicans growth. Coptisine gave big inhibitory zones with diameters between 11 and 43 mm within test range, and the MIC of it was 1000 microg ml(-1).
    CONCLUSIONS:
    Coptisine had strong anti-fungal activity on Candida albicans growth. The method of microcalorimetry applied for the assay of anti-fungal activity of coptisine was quantitative, sensitive and simple. This work will provide useful information for the development of chemical biology policy in the use of anti-microbials in food and drug production.
    Planta Med. 1998 Dec;64(8):758-60.
    Antispasmodic and relaxant activity of chelidonine, protopine, coptisine, and Chelidonium majus extracts on isolated guinea-pig ileum.[Pubmed: 9933996 ]
    Two ethanolic dry extracts from the herb Chelidonium majus L. with a defined content of the main alkaloids (chelidonine, protopine, and coptisisine) and the alkaloids themselves were studied in three different antispasmodic test models on isolated ileum of guinea-pigs.
    METHODS AND RESULTS:
    In the BaCl2-stimulated ileum, chelidonine and protopine exhibited the known papaverine-like musculotropic action, whereas coptisine (up to 3.0 x 10(-5) g/ml) was ineffective in this model. Both extracts were active with 53.5% and 49.0% relaxation at 5 x 10(-4) g/ml. The carbachol and the electric field stimulated contractions were antagonized by all three alkaloids. Coptisine showed competitive antagonist behaviour with a pA2 value of 5.95. Chelidonine and protopine exhibited a certain degree of non-competitive antagonism. In the electric field the antagonist activities decreased in the order protopine > coptisine > chelidonine. The concentrations of the chelidonium herb extracts for 50% inhibition of the carbachol and electrical field induced spasms were in the range of 2.5 to 5 x 10(-4) g/ml.
    2015;43(1):291-302.
    The IDO inhibitor coptisine ameliorates cognitive impairment in a mouse model of Alzheimer's disease[Pubmed: 25079795]
    Indoleamine 2,3-dioxygenase (IDO), the first and rate-limiting enzyme in the kynurenine pathway (KP) of tryptophan catabolism, was recently established as one of the potential players involved in the pathogenesis of Alzheimer's disease (AD). Coptisine is a main pharmacological active constituent of the traditional Chinese medicinal prescription Oren-gedoku-to (OGT) which has therapeutic potential for the treatment of AD. Our recent studies have demonstrated that OGT significantly inhibited recombinant human IDO activity, which shed light on the possible mechanism of OGT's action on AD. Here, we characterized the effects of coptisine in an AD mouse model on the basis of its IDO inhibitory ability. Coptisine was found to be an efficient uncompetitive IDO inhibitor with a Ki value of 5.8 μM and an IC50 value of 6.3 μM. In AβPP/PS1 transgenic mice, oral administration of coptisine inhibited IDO in the blood and decreased the activation of microglia and astrocytes, consequently prevented neuron loss, reduced amyloid plaque formation, and ameliorated impaired cognition. Neuronal pheochromocytoma (PC12) cells induced with amyloid-β peptide 1-42 and interferon-γ showed reduction of cell viability and enhancement of IDO activity, while coptisine treatment increased cell viability based on its reversal effect on the enhanced activity of IDO. In conclusion, our present findings provide further evidence supporting the critical links between IDO, KP, and AD, and demonstrate coptisine, a novel IDO inhibitor, as a potential new class of drugs for AD treatment. Keywords: Alzheimer's disease; coptisine; indoleamine 2, 3-dioxygenase; indoleamine 2, 3-dioxygenase inhibitor; kynurenine pathway.
    2017 Mar;39(3):1010428317694565.
    Coptisine-induced cell cycle arrest at G2/M phase and reactive oxygen species-dependent mitochondria-mediated apoptosis in non-small-cell lung cancer A549 cells[Pubmed: 28351307]
    This study aimed to explore the effect of coptisine on non-small-cell lung cancer and its mechanism through various in vitro cellular models (A549). Results claimed significant inhibition of proliferation by coptisine against A549, H460, and H2170 cells with IC50 values of 18.09, 29.50, and 21.60 μM, respectively. Also, coptisine exhibited upregulation of pH2AX, cell cycle arrest at G2/M phase, and downregulation of the expression of cyclin B1, cdc2, and cdc25C and upregulation of p21 dose dependently. Furthermore, induction of apoptosis in A549 cells by coptisine was characterized by the activation of caspase 9, caspase 8, and caspase 3, and cleavage of poly adenosine diphosphate ribose polymerase. In addition, coptisine was found to increase reactive oxygen species generation, upregulate Bax/Bcl-2 ratio, disrupt mitochondrial membrane potential, and cause cytochrome c release into the cytosol. Besides, treatment with a reactive oxygen species inhibitor (N-acetyl cysteine) abrogated coptisine-induced growth inhibition, apoptosis, reactive oxygen species generation, and mitochondrial dysfunction. Thus, the mediation of reactive oxygen species in the apoptosis-induced effect of coptisine in A549 cells was corroborated. These findings have offered new insights into the effect and mechanisms of action of coptisine against non-small-cell lung cancer. Keywords: A549 cells; Coptisine; apoptosis; cell cycle arrest; cytotoxicity; reactive oxygen species.
    In vivo:
    Lipids. 2015 Feb;50(2):185-94.
    The safety and anti-hypercholesterolemic effect of coptisine in Syrian golden hamsters.[Pubmed: 25547428]
    Current work was conducted to evaluate the cholesterol-lowering effect of coptisine extracted from Rhizoma coptidis in Syrian golden hamsters. The safety results indicated that coptisine was a safe and low-toxic compound.
    METHODS AND RESULTS:
    Coptisine showed a beneficial effect in the abnormal serum lipid levels induced by a high-fat and high-cholesterol diet (HFHC): at a concentration of 70.05 mg/kg, coptisine significantly led to a decrease in total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-c) levels by 26.70, 15.38, and 22.22 %, respectively, and high-density lipoprotein cholesterol (HDL-c) was increased by 41.74 % in serum of hamsters (p < 0.01). In addition, total bile acid (TBA) levels in feces of hamsters were elevated after coptisine administration. Further investigation has suggested that the mRNA and protein expression of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) in the liver of hamsters was down-regulated by high-dosage coptisine treatment (p < 0.05); mRNA and protein expression of low-density lipoprotein receptor (LDLR) and cholesterol 7α-hydroxylase (CYP7A1) were dramatically up-regulated by coptisine administration. The apical sodium-dependent bile salt transporter expression was down-regulated in the coptisine-treated animals, but showed no significant differences from the HFHC groups. Taken together, our results demonstrate that a high dosage of coptisine could inhibit cholesterol synthesis via suppressing the HMGCR expression and promoting the use and excretion of cholesterol via up-regulating LDLR and CYP7A1 expression.
    CONCLUSIONS:
    These findings suggest a critical role for coptisine in anti- hypercholesterolemia, and thus it needs to be considered as a potential natural cholesterol lowering agent.
    Toxicol Lett. 2014 May 2;226(3):328-36.
    Unraveling the novel anti-osteosarcoma function of coptisine and its mechanisms.[Pubmed: 24607417]
    Uncontrolled cell proliferation and robust angiogenesis play critical roles in osteosarcoma growth and metastasis. In this study we explored novel agents derived from traditional Chinese medicinal herbs that potently inhibit osteosarcoma growth and metastasis.
    METHODS AND RESULTS:
    Coptisine, an active component of the herb Coptidis rhizoma, markedly inhibited aggressive osteosarcoma cell proliferation. Coptisine induced cell cycle arrest at the G0/G1 phase through downregulation of CDK4 and cyclin D1 expression and effectively suppressed tumor growth in a xenografted mouse model. Coptisine significantly impeded osteosarcoma cell migration, invasion, and capillary-like network formation by decreasing the expression of VE-cadherin and integrin ß3, and diminishing STAT3 phosphorylation. Coptisine significantly elevated blood erythrocyte and hemoglobin levels while still remaining within the normal range. It also moderately increased white blood cell and platelet counts.
    CONCLUSIONS:
    These data suggest that coptisine exerts a strong anti-osteosarcoma effect with very low toxicity and is a potential anti-osteosarcoma drug candidate.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 3.1219 mL 15.6094 mL 31.2188 mL 62.4376 mL 78.047 mL
    5 mM 0.6244 mL 3.1219 mL 6.2438 mL 12.4875 mL 15.6094 mL
    10 mM 0.3122 mL 1.5609 mL 3.1219 mL 6.2438 mL 7.8047 mL
    50 mM 0.0624 mL 0.3122 mL 0.6244 mL 1.2488 mL 1.5609 mL
    100 mM 0.0312 mL 0.1561 mL 0.3122 mL 0.6244 mL 0.7805 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    硫酸黄连碱; Coptisine sulfate CFN90140 1198398-71-8 C19H15NO8S = 417.4 20mg QQ客服:2159513211
    小檗碱; Berberine CFN98049 2086-83-1 C20H18NO4 = 336.4 20mg QQ客服:2056216494
    盐酸黄连素; 盐酸小檗碱; Berberine hydrochloride CFN99562 633-65-8 C20H18NO4Cl = 371.81 20mg QQ客服:1457312923
    硫酸小檗碱; 硫酸氢黄连素; Berberine hydrogen sulphate CFN90432 633-66-9 C20H19NO8S = 433.43 20mg QQ客服:3257982914
    小檗红碱; Berberrubine CFN90509 15401-69-1 C19H16NO4+ = 322.33 20mg QQ客服:215959384
    表小檗碱; Epiberberine CFN98564 6873-09-2 C20H18NO4 = 336.36 20mg QQ客服:1457312923
    黄连碱; Coptisine CFN99563 3486-66-6 C19H14NO4 = 320.32 20mg QQ客服:215959384
    氯化黄连碱; Coptisine chloride CFN99564 6020-18-4 C19H14NO4Cl = 355.77 20mg QQ客服:215959384
    13-甲基小檗碱; 13-Methylberberine CFN93056 54260-72-9 C21H20ClNO4 = 385.84 5mg QQ客服:215959384

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产